BFC
RLMD icon

Bedel Financial Consulting’s Relmada Therapeutics RLMD Stock Holding History

Bedel Financial Consulting’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$69.6K Hold
10,000
– – 0.01% 293
2025
Q4 		$48.3K Hold
10,000
– – 0.01% 288
2025
Q3 		$20.1K Hold
10,000
– – ﹤0.01% 285
2025
Q2 		$6K Hold
10,000
– – ﹤0.01% 274
2025
Q1 		$3.57K Hold
10,000
– – ﹤0.01% 261
2024
Q4 		$3.8K Hold
10,000
– – ﹤0.01% 267
2024
Q3 		$32.4K Hold
10,000
– – ﹤0.01% 255
2024
Q2 		$30K Hold
10,000
– – ﹤0.01% 249
2024
Q1 		$46.5K Hold
10,000
– – 0.01% 252
2023
Q4 		$41.4K Hold
10,000
– – 0.01% 243
2023
Q3 		$30K Hold
10,000
– – 0.01% 234
2023
Q2 		$24.6K Buy
+10,000
New +$27.6K 0.01% 239

Other funds holding RLMD

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
SSC
Spruce Street Capital New York $416M AUM
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Bedel Financial Consulting's RLMD Position: Q1 2026 in Review

Bedel Financial Consulting held its Relmada Therapeutics (RLMD) position steady in Q1 2026 at 10,000 shares worth $69.6K. The position accounts for 0.01% of the portfolio, ranked #293.

Bedel Financial Consulting first reported a position in RLMD in Q2 2023 and has held it in 12 quarters since. 103 funds tracked by Wall St. Rank hold RLMD as of Q1 2026.

  • Bedel Financial Consulting held 10,000 shares of Relmada Therapeutics worth $69.6K as of Q1 2026.
  • Bedel Financial Consulting left its Relmada Therapeutics share count unchanged in Q1 2026.
  • Relmada Therapeutics made up 0.01% of Bedel Financial Consulting's portfolio in Q1 2026, its #293 holding.
  • Bedel Financial Consulting first reported a position in Relmada Therapeutics in Q2 2023 and has held it in 12 quarters since.
  • 103 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q1 2026.

Based on Bedel Financial Consulting's 13F filing for Q1 2026, filed 4 May 2026.